376 related articles for article (PubMed ID: 36647169)
1. Increasing cure rates of solid tumors by immune checkpoint inhibitors.
Ma W; Xue R; Zhu Z; Farrukh H; Song W; Li T; Zheng L; Pan CX
Exp Hematol Oncol; 2023 Jan; 12(1):10. PubMed ID: 36647169
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer.
Shukla N; Hanna N
Lung Cancer (Auckl); 2021; 12():51-60. PubMed ID: 34234606
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
Jang A; Adler DM; Rauterkus GP; Bilen MA; Barata PC
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680214
[TBL] [Abstract][Full Text] [Related]
5. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
7. The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross-national comparison study.
Jin Y; Li H; Zhang P; Yu M; Zhang H; Li X
Int J Cancer; 2023 Jun; 152(11):2351-2361. PubMed ID: 36632000
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant immunotherapy in gastrointestinal cancers - The new standard of care?
Petricevic B; Kabiljo J; Zirnbauer R; Walczak H; Laengle J; Bergmann M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):834-850. PubMed ID: 35671877
[TBL] [Abstract][Full Text] [Related]
9. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
10. Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China.
Fang W; Zhao S; Zhang Y; Ma Y; Zhao H; Zhang L
Oncologist; 2019 Feb; 24(Suppl 1):S11-S20. PubMed ID: 30819827
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone.
Tang WF; Ye HY; Tang X; Su JW; Xu KM; Zhong WZ; Liang Y
Front Oncol; 2023; 13():1063183. PubMed ID: 36776323
[TBL] [Abstract][Full Text] [Related]
12. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing.
Li Z; Song W; Rubinstein M; Liu D
J Hematol Oncol; 2018 Dec; 11(1):142. PubMed ID: 30577797
[TBL] [Abstract][Full Text] [Related]
13. The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
Li F; Chen Y; Wu J; Li C; Chen S; Zhu Z; Qin W; Liu M; Hu B; Liu S; Zhong W
Chronic Dis Transl Med; 2022 Jun; 8(2):100-111. PubMed ID: 35774424
[TBL] [Abstract][Full Text] [Related]
14. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
Rizvi N; Ademuyiwa FO; Cao ZA; Chen HX; Ferris RL; Goldberg SB; Hellmann MD; Mehra R; Rhee I; Park JC; Kluger H; Tawbi H; Sullivan RJ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918220
[TBL] [Abstract][Full Text] [Related]
15. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
17. Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
Zayac A; Almhanna K
Transl Gastroenterol Hepatol; 2020; 5():9. PubMed ID: 32190777
[TBL] [Abstract][Full Text] [Related]
18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
19. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
20. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC.
Friedlaender A; Naidoo J; Banna GL; Metro G; Forde P; Addeo A
Cancer Treat Rev; 2022 Mar; 104():102350. PubMed ID: 35093800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
